Our Team

A co-founder of Virax Biolabs, James is an Asia-focused investment, product development and distribution expert in the medical device and pharmaceutical sector. He started his career in London with the Royal Bank of Canada. Subsequently, he move to Beijing in 2011 to co-found Emerging Asia Capital a resource focused Mergers & Acquisitions Boutique. He then co-founded Natural Source Group a pharmaceutical & nutraceutical product development and distribution company in 2013 which was subsequently acquired. He attended the School of Oriental & African Studies in London and Stanford University in the USA.

Tomasz has a PhD in Applied Physiology and Ageing from King’s College London. He has 12 years of experience in developing digital healthcare systems focussing on diagnostics, physiological assessments, biochemistry and laboratory analysis. Tomasz has held the position of Chief Scientific Officer for London based Soza Health and Singapore based Verita Healthcare Group. He has also worked in scientific research at Imperial College London and Liverpool John Moore’s University.

Cameron is a co-founder of Virax Biolabs and has a depth of experience in running successful companies and teams across Asia and in The UK. Previous to Virax Biolabs, Cameron co-founded and served as the COO of Natural Source Group, a pharmaceutical and nutraceutical product development and distribution company prior to merging with our Group. Since June 2016, he has been serving as a board member and strategic advisor at Pent Developments Ltd, an award-winning airspace developer and innovator. He also served as the CEO of Merzura Ltd a Hong Kong Investment advisory company, and CEO of Femme 500 Ltd, a luxury lifestyle membership tech startup. He is an alumnus of The University of York before gaining Mandarin fluency at Beijing Language & Culture University.

Mark is a graduate of Cambridge University and a Chartered Accountant (ACA -ICAEW). He specialises in transforming businesses through the use of technology and improved structure and process to improve their support systems performance. The industries worked he has worked across include telecoms, retail and government and for companies including KPMG and the UK’s Ministry of Justice. Mark has been based in Shanghai for the last two years.

Jason previously acted as CFO for Hyperdynamics Corporation. He first joined the company in June 2009 as the Chief Financial Officer and subsequently held the position of Vice President of Finance and Treasurer from August 2010 to December 2014. Jason is a licensed certified public accountant and has served in various financial positions for several companies, including as the Chief Financial Officer of CASA Exploration from May 2015 to May 2017, Assistant Controller at Isolagen, Inc. from March 2004 to August 2005, the Manager of SEC Reporting at Texas Genco, LLC from August 2005 to June 2006, and the Controller at Particle Drilling Technologies, Inc. from June 2006 to June 2009. He also served as the interim Chief Financial Officer for Particle Drilling Technologies, Inc. from January 2009 to June 2009.

Peggy Gilmour is a senior finance, risk management and audit executive with a deep understanding of both US and Canadian regulatory environments. Most recently, Ms. Gilmour was Board Chair of the Institute of Internal Auditors, Toronto Chapter, and has previously held board, audit, governance & risk roles with organizations such as Metrolinx, Interac and Ontario Pension Board. A chartered accountant by training, Ms. Gilmour gained her extensive finance experience as CFO of the Operations & Technology Division within BMO Financial Group and as SVP of Finance at Aviva Insurance Canada.

Yair is currently a Partner at Bain & Company, where he work with Private Equity investors across the investment cycle -deal sourcing, buy side diligence, post acquisition work and exit support, with a focus on the healthcare and life sciences industries (Pharma, Med-Tech, Software, Outsourced Service Providers, Healthcare Providers, Animal Health and other verticals). Previously he was a Partner at McKinsey & Company, and a practicing Obstetrician and Gynaecologist.

Evan joined Abbott in 2010, as Director of Abbott Ventures and took over primary responsibility for the organization in 2014. Prior to joining Abbott, he was a Principal at ONSET Ventures. He also held positions at Acclarent, Inc., Johnson & Johnson, Stryker Corporation, JPMorgan and PwC. Evan attended Texas A&M University and received his Bachelor of Business Administration in Finance. He also holds a MBA from Northwestern’s Kellogg School of Management where he is an adjunct lecturer in the Kellogg Innovation and Entrepreneurship Initiative.

Currently, Karen is acting contract Chief Marketing Officer engaged with numerous innovative and disruptive technology organisations across Financial Markets, Healthcare, eCommerce, and Digital Assets. She is the former Chief of Client Services & Marketing at a Quantitative Machine Learning Hedge Fund now focused on publicly listed Life Science and Biotech Technology companies. Karen is the former Senior Marketing Advisor at Securrency, RegTech Global Infrastructure funded by US Bank, State Street and Wisdom Tree. She is also Advisor to OneChronos, a Y Combinator graduate, focused on delivering an AI powered Dark Pool. Karen is Director to UK based Gold Leaf Cannabis Fund with the founding member of Trivial Pursuit. Her exits include serving as Chief Marketing Officer to Zenedge (sold to Oracle) Chief Marketing Officer to Perseus (sold to GTT) Chief Marketing Officer of Fixnetix (sold to CSC) Head of Communications Strategy to 7Ticks, (sold to IDC now NYSE ICE) Mirus Futures (sold to NinjaTrader) and Trader Kingdom. MBA, California Polytechnic University.

Having studied in France and Germany, Pierre Frouin received his Masters of Science in Electronics and IT in 2005. He started his career in Vietnam working for Servier, a French pharmaceutical company, where he was in charge of developing and deploying IT systems focused on sales force management.

After three years, he moved back to Europe where he worked on deploying SAP for Biogaran, an industry leader in the manufacturing of generic drugs. After completing his MBA at Insead in 2011, Pierre moved to the USA to join the leadership team of Johnson & Johnson in the field of medical diagnostics. As Manager of Marketing and Sales, he focused on commercial operations.

With broad experience in the healthcare industry, Pierre-Yves founded BioSerenity in Paris in 2014, an innovative company based in the Brain and Spine Institute (icm-institute.org), with whom the company shares a common laboratory focused on the use of A.I. for the digital detection of biomarkers. Active on three continents, and a recipient of many awards, BioSerenity aims to develop and deploy connected medical solutions in partnership with healthcare facilities and industries to help the diagnosis and monitoring of patients with chronic diseases.

Today, BioSerenity works with more than 200 hospitals in Europe and the USA. BioSerenity has helped diagnose and monitor tens of thousands of patients and has recently announced the fund raising of 65 million euros to support its growth.

Dr. Levner co-founded Sight, with a desire to bring AI and data sciences to diagnostics. With a career that spans engineering and biology, Dr. Levner brings to Sight his extensive experience in diagnostics, instrument development, and cell biology. This unusual background gives Dr. Levner a unique perspective on how technology and biology inter-operate in a complete and complex product. Dr. Levner was a Senior Scientist at Harvard’s Wyss Institute for Biologically Inspired Engineering, he co-founded two other biology and engineering companies, and trained with world-renowned geneticist Dr. George Church. Dr. Levner holds a Ph.D. in Electrical Engineering from Stanford University, an M.S. in Aeronautics and Astronautics from Stanford University and B.A.Sc. in Engineering Science from the University of Toronto.

Nikolas Perrault is the founder of Twilight Capital Over the past 25 years, which include 17 years working for several large Investment Banks, he has developed an extensive international relationship network. Twilight provides Capital Market and M&A advisory services to select clients globally. Its main focus is technology and natural resource industries.

Lawrence Rhee is a investment banking and structuring expert who graduated with an MBA from the University of Toronto, has been actively involved with the Canadian tech industry for 20 years and has held senior positions in both investment banking and equity research at several firms including Haywood Securities, GMP Securities and Genuity Capital.

Dr Hampson has had over 35 years experience in cancer research since obtaining his PhD studying the biochemistry of complex carbohydrates at the University of Manchester Paterson Laboratories in 1982. He has Developed the pathology of angiogenesis which was best exemplified by a landmark paper in Science in 1985 "Angiogenesis induced by degradation products of hyaluronic acid" which now has over 1000 citations. In 1997 he took up my current post of senior lecturer in gynaecological oncology at the University of Manchester, was promoted to Reader in 2013 and Chair of Viral Oncology in 2017. He discovered of a new use for the HIV drug lopinavir as a treatment for HPV related cervical dysplasia. Subsequently carrying out preclinical work on this indication which resulted in a phase 1 clinical trial in Nairobi (Hampson et al 2016, PloS One)

Dr. Bruce Lavin is Vice President, Head of External Engagement and Policy and Medical Affairs, in the Neurology Division of UCB Pharma, and is Adjunct Professor of Biomedical Science at Georgia State University. He is also a practicing physician in Internal Medicine, Infectious Diseases, and Critical Care. Bruce joined UCB in September of 2013 as Vice President, US Medical Affairs.

Prior to joining UCB, Bruce held various executive level medical positions in the pharmaceutical industry and several clinical positions at academic medical centers, working in Clinical Development and Medical Affairs leadership roles at Sanofi-Aventis, Novartis, and Bristol-Myers Squibb. He had faculty and clinical positions at the University of California, San Francisco and Davis. He serves on the Executive Boards of Georgia Tech, Morehouse College, Cobb County Chamber of Commerce, and AMSUS (Association of Military Surgeons of the US).

Bruce earned his Doctor of Medicine degree from the Uniformed Services University of the Health Sciences. He also earned a Master of Public Health degree in Health Policy and Administration from UCLA School of Public Health and the School of Business Administration. Bruce attended American University, Western College of Law for his first-year law studies.

Marc has 30 years of experiences of entrepreneurship and R&D in High Technology and Medical Device. Including component design, electronics, micro-mechanics and complex integrated products. 7 years of experience of as investor including Angel and Venture capital. Marc has a special focus on early deployment made possible by advanced in micro-electronics and high technology to bring to market innovative solutions.

Marc leads currently the R&D and early market introduction of the pathology specific solutions of Bioserenity. Bioserenity is a French innovative company based in Paris largest hospital developing long term diagnostic and monitoring solutions for critical long term Pathologies in cardio, neuro, uro, maternity and sleep disorder. The solutions are based on second skin textile, flexible electronics, Cloud with IoT, data science and AI software. The company has a special focus on helping with diagnostics and monitoring that required long term measure for rare events like Epilepsy Seizures or cardio Arithmia.

Assi is growth orientated entrepreneur. Previously, he led Sight Diagnostics' global growth efforts, working with players from across the healthcare system to accelerate impact on patients' lives. Scaled the commercial team from scratch.

Prior to joining Sight, he worked as Data Intelligence Director for the Very Group, the UK’s second largest pureplay online retailer. he led the consumer and market research, analytics, data strategy, and data science departments, through a high-impact, fun and exciting transformation and growth.

Before Very, he was an Associate-Partner at McKinsey and Company, where I worked with retailers, CPGs and other consumer-facing companies on topics such as growth strategy, commercial improvement and customer experience.

Laith is a professor of epidemiology at the London School of Hygene & Tropical Medicine (LSHTM). He was one of the founding eight core members of the UK Public Health Rapid Support Team, who support countries responding to disease outbreaks before they can develop into a global threat. He was also a founding member of the Antimicrobial Resistance Centre at LSHTM, where I previously acted as the disciplinary head for Epidemiology and Modelling.

Greg served as a corporate development director of ISG Limited, an international services construction company, a managing director in a number of mid-capital-market-focused investment banks in London, the chief financial officer and subsequently the managing director of Gamlestaden plc, the London subsidiary of Natwest Group, and a manager in the audit department of Peat Marwick Mitchell & Co., a public accounting company in South Africa. Greg received a bachelor’s degree in commerce from University of Witwatersrand and a postgrad diploma in accounting from the University of Cape Town. He also received a master of business administration from City University, London and qualified as a Chartered Accountant.